Protollin is a drug initially formulated as a vaccine adjuvant.[1][2] It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas shigelloides bacterium combined with hydrophobic outer membrane proteins derived from Neisseria meningitidis.[3] [4]
On November 16, 2021, Brigham and Women's Hospital announced that it was beginning a Phase I clinical trial of Protollin as a nasally-delivered vaccine to activate the body's immune response against amyloid proteins that form in the brain and are thought to contribute to the symptoms of Alzheimer's disease.[5][6]
References
edit- ^ "Human trials for nasal Alzheimer's vaccine due to start". Newsweek. 2021-11-17. Retrieved 2021-11-19.
- ^ "First human trial of Alzheimer's disease nasal vaccine to begin at Boston hospital". www.cbsnews.com. CBS News. 16 November 2021. Retrieved 2021-11-19.
- ^ JONES, T; ADAMOVICZ, J; CYR, S; BOLT, C; BELLEROSE, N; PITT, L; LOWELL, G; BURT, D (2006-03-06). "Intranasal Protollin™/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection". Vaccine. 24 (10): 1625–1632. doi:10.1016/j.vaccine.2005.09.052. ISSN 0264-410X. PMID 16243411.
- ^ Jones, Taff; Cyr, Sonya; Allard, Francine; Bellerose, Nathalie; Lowell, George H; Burt, David S (September 2004). "Protollin™: a novel adjuvant for intranasal vaccines". Vaccine. 22 (27–28): 3691–3697. doi:10.1016/j.vaccine.2004.03.035. PMID 15315848.
- ^ "BWH Press Release - Brigham and Women's Hospital". www.brighamandwomens.org. Retrieved 2021-11-18.
- ^ Jones, Taff; Cyr, Sonya; Allard, Francine; Bellerose, Nathalie; Lowell, George H.; Burt, David S. (2004-09-09). "Protollin: a novel adjuvant for intranasal vaccines". Vaccine. 22 (27–28): 3691–3697. doi:10.1016/j.vaccine.2004.03.035. ISSN 0264-410X. PMID 15315848.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |